Asthma treatment

181. – January 18, 2009 FDA still investigating the safety of Singulair AGENCY SAYS IT NEEDS MORE TIME TO FIGURE OUT WHETHER THE ASTHMA DRUG LEADS TO A HIGHER RISK OF SUICIDE WASHINGTON The Food and Drug Administration said in March it was reviewing a handful of reports involving mood changes, suicidal behavior and suicide in patients who had taken Singulair. The drug is commonly prescribed to prevent asthma flare-ups in adults and children. Now, more than nine months later, the agency says it still has not reached a conclusion and will continue its investigation of Singulair and similar drugs. First approved in 1998, Singulair was ….. Birmingham Post, The (England) – August 7, 1998 The Birmingham Post: Insider: Zeneca faces a few nervous months waiting for the drugs to work Being the target of persistent bid peculation cannot be much fun for Zeneca management. It has meant a bumpy ride for the shares and a distraction for the board. The shares bottomed out at 2, 184p after half-time results yesterday before recovering to trade at 2, 776p. This compares with some 2, 850p at the height of takeover fever in April. It has still been a star performer, however. And the half-year figures, showing a disappointing fall because of one-off costs, disguised a strong ….. Times, The (London, England) – August 8, 1997 Zeneca, Tempus SOME idea of Zeneca’s strengths can be gauged from the recent City worries centred on Zestril, the Pounds 600 million-a-year heart drug whose patent does not expire until the end of 2001. Sir David Barnes yesterday acknowledged that the loss of sales could mean Zeneca’s earnings growth will drop below 10 per cent from 2002, but this is a problem the company has four-and-a-half years to fix. Crisis this is not. In the meantime, the company’s 15 per ….. Daily Mirror, The (London, England) – April 20, 2004 The Mirror: Sorted and the City: Nokia-on effect TAKEOVER talk and phone firms helped the FTSE push ahead as it added 0. 2 per cent to 4546. 2. It had spent most of the day in the doldrums due to gloom over oil companies. BP lost one per cent to 492p on news that Opec was increasing oil supplies to cut crude prices. Phone groups mm02 and Vodafone gained as Nokia cut handset prices in a bid to boost sales. That means the mobile firms can reduce subsidies and mm02 gained 1. 8 per cent to 101. 75p while Vodafone put on two per cent to ….. Los Angeles Times – October 30, 1997 Drug Ads Have Magazines Feeling Good You see the ads all over. Commuter trains carry posters touting the prescription drug Claritin “for seasonal allergy relief” and others for Zyban (”It’s here”), a pill to help smokers quit. On prime-time TV, the makers of Allegra, another allergy fighter, have been hammering its name into viewers’ heads. In magazines and newspapers, a full-page ad asks: “At your age, with your high cholesterol, ….. THE – December 17, 1996 Asthma Sufferers Get Help A new class of asthma drugs offers a radically different line of attack against one of the most common — and fastest-growing — health problems in the United States. Known as “anti-leukotrienes, ” the first two of the new prescription drugs were just approved for U. S. marketing by the Food and Drug Administration: Zyflo (zileuton), from Abbott Laboratories, and Accolate (zafirlukast), manufactured by Zeneca Pharmaceuticals. Both come in pill form, which ….. – March 22, 1999 Effect of inhalers on asthma varies Q: In light of recent warnings about cortisone inhalers and children’s growth, I took my 14-year-old son off his. When he tried alternative treatments, he was a mess. He started back on the spray and his symptoms disappeared in days. Is his body addicted to the spray? — S. A. A: Cortisone inhalers have revolutionized asthma treatment. On the downside, they might stunt growth. Uncontrolled asthma might stunt growth, too. Many factors can stop a child from attaining the height ….. Financial Times (London, England) – September 28, 1996 London Stock Exchange: Pharmaceuticals Pharmaceuticals, Pharmaceuticals. Pharmaceuticals moved sharply higher yesterday, dragged up by a raft of positive news. Glaxo Wellcome hit a new closing high with a rise of 18 to 994p, Zeneca bounced 33 to 1580p and SmithKline Beecham improved 16 1/2 to 771p. Between them, they accounted for about 8 points of Footsie’s rise yesterday. The most significant development came from Pfizer of the US, which gave approval late on Thursday for the repurchase of up to Dollars 2bn of ….. (NY) – March 22, 1999 INHALERS REVOLUTIONIZE TREATMENT OF ASTHMA Dear Dr. Donohue: In light of recent warnings about cortisone inhalers and children’s growth, I took my 14-year-old son off his. When he tried alternative treatments, he was a mess. He started back on the spray and his symptoms disappeared in days. Is his body addicted to the spray? – S. A. Cortisone inhalers have revolutionized asthma treatment. On the downside, they might stunt growth. Uncontrolled asthma might stunt growth, too. Many factors can stop a child from attaining the …. 0. (CA) – February 24, 1998 STOCK OF THE DAY Merck & Co. shares climbed $5. 94 to $130. 63 on Monday after the Food and Drug Administration cleared the drugmaker to begin selling its Singulair asthma drug next month. Singulair is one of a new class of oral asthma drugs that targets the causes of the disease, rather than symptoms. The first such drug to win FDA approval was Zeneca Group’s Accolate. ….